Hofseth Biocare ASA ( (HOFBF) ) has shared an announcement.
Hofseth BioCare ASA announced a strategic partnership with Symrise to expand its manufacturing and market reach by constructing a second enzymatic hydrolysis plant in Norway, supported by a EUR 5 million loan from Symrise. This collaboration aims to enhance HBC’s production capacity, promote their marine ingredients globally, and strengthen their position as leaders in science-led marine nutrition, benefiting both companies’ portfolios and market presence.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company specializing in consumer and pet health products, founded on principles of sustainability and optimal resource utilization. The company focuses on upcycling salmon industry by-products into bioactive ingredients such as ProGo, OmeGo, and CalGo, which are designed to enhance human and pet health.
Average Trading Volume: 21,200
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $97.39M
Find detailed analytics on HOFBF stock on TipRanks’ Stock Analysis page.